CD8A and acute myeloid leukemia: SLC27A2 participates in the immune process of hematological tumors through T cell CD8 + and macrophages, In DLBCL, patients with low expression of SLC27A2 have poorer prognosis, while in AML, patients with high expression of SLC27A2 have poorer prognosis (Fig. S4).